Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PRLD
SellHot AirPrelude Therapeutics Incorporated · Healthcare · United States · $437M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Prelude Therapeutics Incorporated is a clinical-stage biotechnology company focused on developing small molecule therapies for cancer, particularly targeting key oncology pathways. The company's pipeline includes candidates designed to inhibit specific protein targets involved in tumor growth and progression. Its competitive moat relies on its robust drug discovery platform and the potential of its selective inhibitors to address unmet needs in oncology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 7.0M | 12.1M | 73.4% | 22.4M | 66.1M | 56.7M | 116.0% |
| EPS | -2.44 | -2.02 | -1.68 | -1.29 | — | -0.73 | -0.54 | -0.75 | — |
| Shares | 47.9M | 54.9M | 55.1M | 63.0M | +31.4% | 65.1M | — | — | — |
| Debt | 1.8M | 16.9M | 18.0M | 17.8M | 113.3% | 17.6M | — | — | — |
| Equity | 195.4M | 237.1M | 131.5M | 68.6M | -29.4% | — | — | — | — |
| Op CF | -83.7M | -107.1M | -102.9M | -56.3M | — | -33.3M | — | — | — |
| Inv CF | 81.7M | -34.6M | 90.2M | 53.5M | — | — | — | — | — |
| Fin CF | 0.8M | 136.4M | -0.1M | 24.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PRLD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PRLD | Prelude Therapeutics Incorporated(you) | $437M | 25 | Sell |
| ARCT | Arcturus Therapeutics Holdings Inc. | $432M | 25 | Sell |
| XFOR | X4 Pharmaceuticals, Inc. | $401M | 26 | Sell |
| PRTC.L | PureTech Health plc | $415M | 27 | Sell |
| BNTC | Benitec Biopharma Inc. | $428M | 23 | Sell |
| CCCC | C4 Therapeutics, Inc. | $474M | 27 | Sell |
| RZLT | Rezolute, Inc. | $445M | 21 | Sell |
| RLMD | Relmada Therapeutics, Inc. | $462M | 20 | Sell |
| DNA | Ginkgo Bioworks Holdings, Inc. | $469M | 20 | Sell |
| SABS | SAB Biotherapeutics, Inc. | $345M | 23 | Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%